PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)

  • End date
    Dec 19, 2024
  • participants needed
  • sponsor
    Eric Thompson, M.D.
Updated on 19 June 2022
karnofsky performance status
initial diagnosis
brain mri
neutrophil count
malignant glioma
recurrent tumor
montanide isa-51


The primary goal of this prospective clinical trial is to evaluate the safety of PEP-CMV in patients with recurrent medulloblastoma and malignant glioma. Patients with histologically-proven medulloblastoma or malignant glioma who had received prior therapy for their initial diagnosis and subsequently had tumor recurrence/progression may be enrolled any time after recurrence/progression regardless of prior adjuvant therapy. PEP-CMV is a vaccine comprised of Component A, a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. In May 2021, enrollment on the study was temporarily suspended due to delays in vialing the PEP-CMV study vaccine.


Once a patient has enrolled onto this study, prior therapy will be terminated and patients will receive temozolomide 200 mg/m2/day x 5 days. If they are receiving bevacizumab at the time of enrollment, they will continue bevacizumab 10 mg/Kg every 14 days.

Patients who are ≥ 18 years of age will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Tetanus (Td) pre-conditioning vaccine delivered intradermally (i.d.) in the right groin at the site of the vaccine injection 6-24 hours prior to the first vaccine on day 21. The PEP-CMV vaccine will be administered as follows: PEP-CMV Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

The first 3 PEP-CMV vaccines will occur every 2 weeks, then PEP-CMV vaccines will continue monthly (+/- 2 weeks) for no more than 10 years. Blood will be obtained for immune system monitoring.

In May 2021, enrollment on the study was temporarily suspended due to delays in vialing the PEP-CMV study vaccine.

Condition Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood, Malignant Glioma
Treatment PEP-CMV
Clinical Study IdentifierNCT03299309
SponsorEric Thompson, M.D.
Last Modified on19 June 2022


Yes No Not Sure

Inclusion Criteria

Patients who are 3 - 35 years old
Histopathologically proven previous diagnosis of medulloblastoma or Grade III or IV glioma
Radiology evidence of recurrent medulloblastoma (reMB) or recurrent Grade III and IV glioma. Patients will be considered for a biopsy or resection of the recurrent/progressive tumor at the discretion of the treating neurosurgeon and neuro-oncologist
Brain MRI within one month prior to enrollment
Received prior therapy for their initial diagnosis prior to recurrence/progression or who are unable to receive radiation therapy due to genetic disorders that put them at significant risk for radiation-induced secondary malignancies (i.e. Gorlin's syndrome or NF1 mutation)
Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to registration
Karnofsky Performance Status (KPS) of ≥ 60% (KPS for > 10 years of age) or Lansky performance Score (LPS) of ≥ 60 (LPS for ≤ 10 years of age) assessed within 2 weeks prior to registration. Patients who are unable to walk because of paralysis but who are up in a wheel chair will be considered ambulatory for the purposes of the performance score
Bone Marrow
ANC (Absolute neutrophil count) ≥ 1000/µl (unsupported)
Platelets ≥ 100,000/µl (unsupported)
Hemoglobin > 8 g/dL (may be supported)
• Serum creatinine ≤ upper limit of institutional normal
Bilirubin ≤ 1.5 times upper limit of normal for age
SGPT (ALT) ≤ 3 times institutional upper limit of normal for age
SGOT (AST) ≤ 3 times institutional upper limit of normal for age
Patients of childbearing or child-fathering potential must be willing to use a
medically acceptable form of birth control, which includes abstinence, while
being treated on this study
Signed informed consent according to institutional guidelines must be obtained prior to registration
Any prior chemoradiotherapy is allowed

Exclusion Criteria

Pregnant or need to breast feed during the study period (Negative serum pregnancy test required)
Active infection requiring treatment or an unexplained febrile (> 101.5 degrees F) illness
Known immunosuppressive disease or human immunodeficiency virus infection
Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease
Patients receiving concomitant immunosuppressive agents for medical condition
Patients who need definitive radiotherapy for treatment of recurrent MB or recurrent Grade III or IV glioma
Patients receiving any other investigational drug therapy
Patients on corticosteroids > 0.1 mg/Kg/day (i.e. > the maximum dose of 4 mg/day)
Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction)
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note